Advanced Nanotechnology Ltd reports sales to customers for the September 2007 quarter were $960,000, up 102pc from $474,000 in the June 2007 quarter and up 188pc from $333,000 in the September 2006 quarter.
The Nano-Network and NanoBusiness Alliance, today announced corporate event sponsors and additional keynote speakers for the 2007 Nano App Summit, to be held October 22-25, 2007, at the Ritz Carlton Hotel in Cleveland, Ohio.
BIND Biosciences, Inc., a privately held biopharmaceutical company developing therapeutic targeted nanoparticles, announced today that it has received a three year $2,000,000 award from the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP) to further develop its platform for high-throughput formulation and selection of targeted nanoparticles.
Nanotherapeutics, Inc., today announced that it has been awarded a $20 Million 4-year contract from the National Institute of Allergy and Infectious Diseases to develop an inhaled version of the injectable drug, gentamicin, a broad-spectrum antibiotic that is used as a first-line therapy for pneumonic plague and tularemia, Category A bioterrorism agents.
Non-profit NanoBioNexus (NBN) - already widely acclaimed for its educational forums and nanobiotechnology expertise in the United States, has moved into the international leadership circles for innovative technologies with its International Alliance Initiative.
Houston Technology Center and Gulf Coast RCIC honored the nine Gulf Coast region companies that received awards from the ETF to date. Total ETF funding thus far to Gulf Coast region companies is over $13 million.
The Piedmont Triad Partnership has awarded seven new Focus Grants in three categories under the WIRED Focus Grants program. The grants program is one of several strategies being employed by the PTP to enhance workforce development initiatives as part of a larger effort to improve the global competitiveness of the Piedmont Triad Region.
Pharmaceuticals, Inc., a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, today announced that eight abstracts on ferumoxtytol, its lead product candidate, have been accepted for presentation at the American Society of Nephrology meeting.